Repligen (RGEN) Expected to Release Quarterly Earnings on Tuesday

Repligen (NASDAQ:RGEN) is expected to issue its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $201.3980 million for the quarter. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:00 AM ET.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.25 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the previous year, the company earned $0.39 EPS. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Stock Performance

Shares of Repligen stock opened at $145.49 on Tuesday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.21 billion, a PE ratio of 161.66, a price-to-earnings-growth ratio of 2.84 and a beta of 1.06. The company has a 50 day moving average of $129.28 and a 200-day moving average of $133.14. Repligen has a 1-year low of $100.99 and a 1-year high of $175.77.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RGEN. Mercer Global Advisors Inc. ADV acquired a new stake in Repligen during the 4th quarter worth approximately $204,000. Polar Capital Holdings Plc acquired a new position in Repligen in the 4th quarter valued at approximately $202,000. Kestra Advisory Services LLC bought a new position in shares of Repligen during the fourth quarter valued at $150,000. UMB Bank n.a. raised its stake in shares of Repligen by 13.8% during the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 92 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in shares of Repligen during the third quarter worth $169,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent analyst reports. Roth Capital assumed coverage on Repligen in a research note on Friday, April 17th. They set a “buy” rating and a $160.00 target price for the company. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. JPMorgan Chase & Co. lowered their price target on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Barclays upped their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Wolfe Research assumed coverage on Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $165.00.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.